China Biologic Products (NASDAQ:CBPO) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.
Separately, Zacks Investment Research raised China Biologic Products from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $137.50.
China Biologic Products (CBPO) opened at $79.95 on Tuesday. The company has a market capitalization of $2,620.00, a P/E ratio of 20.82, a price-to-earnings-growth ratio of 1.00 and a beta of 1.67. China Biologic Products has a twelve month low of $72.21 and a twelve month high of $120.46.
Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new position in China Biologic Products in the 4th quarter valued at approximately $117,000. Legal & General Group Plc raised its holdings in China Biologic Products by 41.2% in the 3rd quarter. Legal & General Group Plc now owns 2,966 shares of the biopharmaceutical company’s stock valued at $274,000 after acquiring an additional 865 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in China Biologic Products by 73.2% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 4,617 shares of the biopharmaceutical company’s stock valued at $426,000 after acquiring an additional 1,952 shares in the last quarter. State of New Jersey Common Pension Fund D acquired a new position in China Biologic Products in the 3rd quarter valued at approximately $439,000. Finally, Strs Ohio acquired a new position in China Biologic Products in the 3rd quarter valued at approximately $664,000. 52.44% of the stock is owned by hedge funds and other institutional investors.
WARNING: “China Biologic Products (CBPO) Upgraded at BidaskClub” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/13/china-biologic-products-cbpo-upgraded-at-bidaskclub.html.
About China Biologic Products
China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.